NCT00039481View on ClinicalTrials.gov

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

October 31, 2005

Conditions

Cardiac ToxicityUnspecified Childhood Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL

oblimersen sodium

Given IV

DRUG

dexrazoxane hydrochloride

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

cyclophosphamide

Given IV

BIOLOGICAL

filgrastim

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

91006-3776

Children's Oncology Group, Arcadia

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00039481 - Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter